蕈样肉芽肿的复发率和治愈率，有最新数据吗？

会有曙光的

想问一下现在蕈样肉芽肿晚期的移植复发率和成功率是不是还是很高？有没有最新的数据呢？

来自苹果APP客户端

弥漫大b123456

来自安卓APP客户端

橙色雨丝

Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been noted to be a potential curative treatment in cases of advanced-stage mycosis fungoides (MF) or Sezary syndrome (SS). To assess outcomes of allo-HSCT for MF/SS we performed a systematic review and meta-analysis including 15 manuscripts and 557 patients, published from 2010–2023. Meta-analysis revealed 1-year and 3+year overall survival (OS) of 51% (95% CI 39–64%) and 40% (32–49%). Progression-free survival at 1 year and 3+years were 42% (31–53%) and 33% (25–42%). Non-relapse mortality was 18% (13–23%). Relapse occurred in of 47% (40–53%) with a median time to relapse of 7.9 months (range 1.6–24 months). Rates of acute and chronic graft-versus-host disease (GVHD) were 45% (35–55%) and 40% (33–48%). Reduced-intensity conditioning (RIC) was associated with superior OS compared to myeloablative conditioning (MAC) (58% vs. 30%, p < 0.001). Of patients with relapse after allo-HSCT, 46% treated with donor lymphocyte infusion (DLI) achieved complete remission. These data support use of allo-HSCT for treatment of advanced-stage MF/SS and suggest superiority of RIC over MAC. Rates of GVHD were comparable to allo-HSCT in general. The improved OS for RIC and high rate of CR with DLI underscore the importance of the graft-versus-lymphoma effect in allo-HSCT for MF/SS.